Home › NCT03684018

Two Dose Levels of Privigen in Pediatric CIDP

Randomized Study of Two Dose Levels of Privigen in Pediatric CIDP

Who can join

Ages 2 to 17 · All sexes

Inclusion Criteria:

* \- Male or female subjects 2 to ≤ 17 years of age with confirmed or possible CIDP.

Exclusion Criteria:

* \- Absence of CIDP symptoms
* -History or family history of inherited neuropathy
* -Diagnosed developmental delay or regression
* -History of thrombotic episode
* -Known or suspected hypersensitivity to Privigen
* -Known allergic or other severe reactions to blood products
* -Female subject of childbearing potential either not using or not willing to use a medically reliable method of contraception or not sexually abstinent during the study
* -Pregnant or breastfeeding mother"

About the study

A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment

What is being tested

• IgPro10 (biological)

Sponsor: CSL Behring · Participants: 30 · Started: Feb 28, 2019

Contact the study team

• Trial Registration Coordinator · Phone: 6108784697

Official record on ClinicalTrials.gov — NCT03684018

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.